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1. Introduction     
Modern Tissue Engineering represents a highly complex interdisciplinary branch of science 
which brings the life sciences and engineering together to design innovative solutions for 
the treatment of critical tissue defects after traumatic or degenerative damage. In this area an 
interesting evolution can be observed in the approach to achieve this goal: Originally 
understood as a principally biomaterial-based strategy using natural and synthetic materials 
as implants to be integrated into the neighbouring tissue, during the last two decades a 
change of paradigm has taken place which involves a movement away from the structural 
replacement of damaged tissue towards strategies to regenerate functional tissue 
(Kirkpatrick et al., 2006). In this approach cells play an important role, for example in 
seeding scaffold materials, which give a preformed structure for the regenerating tissue. A 
major aim is the synthesis of so-called tissue-like structures in vitro which can be implanted 
in the damaged tissue site and should be integrated into the body’s own tissue. Relevant 
obstacles to this strategy are the proper morphological integration of the cell-material 
construct in the structural context of the damaged tissue site as well as the maintenance of 
its function. The use of cells in combination with different biomaterials gives an important 
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input for the further development of innovative materials with the important aims of 
preserving cell viability, improving the cell seeding efficiency of a scaffold material and by 
this to enhance their functionality.  
Due to the limited regenerative potential of cartilage, traumatic damage to articular cartilage 
is a unique example for the clinical relevance of tissue engineering strategies to treat 
damaged tissue. In this context, the establishment of the autologous chondrocyte 
transplantation by Brittberg et al. (1994) represents the first innovative step to treat articular 
cartilage damage via tissue engineering. With the help of a syringe a suspension of ex vivo 
expanded chondrocytes was injected into the defect which had been covered with a 
periosteal flap. The current approach involves the expansion and transplantation of the 
autologous chondrocytes with the help of a matrix. For this pupose different material-based 
matrices are already on the market and have been developed to provide the seeded cells 
with a suitable biomimetic microenvironment. 
Modern tissue engineering approaches integrate the combined use of cells, scaffolds, and 
growth factors or signalling molecules respectively. There is the hope that such molecules 
will stimulate the controled proliferation and proper differentiation of the seeded cells in the 
scaffold. Furthermore, growth factors should also enhance the migration, proliferation, and 
differentiation of cells from the edges of the treated defect. Thus, such factors can serve first 
to optimize tissue engineered cell-scaffold constructs in vitro, and second to improve their 
performance and integration in vivo. For the targeting of potential signalling molecules and 
growth factors it is important to realize that regeneration in part recapitulates 
developmental processes. Therefore, it can be postulated that for the improvement of 
regeneration in the context of tissue engineering it is essential to understand the regulation 
of developmental processes (Reddi, 2003). With this porpose in mind our group has 
demonstrad that the growth plate of the long bones represents a suitable developmental 
model to target interesting molecules for tissue engineering application of cartilage and 
bone (Brochhausen et al., 2009). 
In this contribution we firstly focused on the structural organization and regulation of the 
growth plate. Based on this we present the development of an integrated release-system in 
an oriented gelatine-based scaffold material for cartilage tissue engineering. 
 
2. Long bone development and endochondral ossification 
Two different steps in bone development are distinguishable, both being important for 
potential tissue engineering strategies: first, the condensation of mesenchymal cells as a 
morphological template and its development to a cartilaginous template during fetal 
development, and second, the longitudinal growth of the long bones within the area of 
endochondral ossification (fig. 1). In the present report we very briefly present the process of 
foetal bone development and then concentrate on endochondral ossification and its 
regulation. 
 
 
 Fig. 1. Schematic depiction of bone development from the hyaline cartilage model to the 
ossified bone with the growth plate as the epicentre of the long bone growth. 
 
The growth plate of long bones represents the epicentre of the long bone longitudinal 
growth. In this structurally highly organized region between the epiphysis and the 
metaphysis of the bone a cartilaginous template is responsible for longitudinal growth, 
which results in terminal ossification and thus leads to the elongation of the long bone 
(fig.2). The characteristic features of this region are chondrocytes in different proliferation 
and differentiation stages integrated in a scaffold of oriented extracellular matrix 
components, mainly consisting of different types of collagen. Since proliferation and 
differentiation in this region is a well regulated process the growth plate can be divided into 
characteristic horizontal zones. In these zones not only the chondrocytes showed a specific 
phenotype, but also specific types of collagen can be found within the different zones. 
 
2.1 The resting zone  
The zone closest to the epiphyseal cartilage is the smallest zone, called the resting zone. The 
latter consists of monomorphic, small chondrocytes with large central nuclei and a narrow 
cytoplasmatic rim. Nowadays, the resting zone cells are seen as being the cell pool for the 
adjacent proliferative zone, since they contain so called “stem-like” cells to supply new 
clones of proliferative zone chondrocytes. This hypothesis could be confirmed by findings of 
Abad et al. (2002), who demonstrated that, after removing the proliferative and the 
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hypertrophic zones of the growth plate, a complete proliferative and hypertrophic zone was 
regenerated, based on cells from the residual resting zone alone. Furthermore, the 
chondrocytes of the resting zone might produce a morphogen, so-called Growth Plate-
Orienting Factor (GPOF) that directs the alignment of proliferative clones into columns 
parallel to the long axis of the developing bone. The GPOF diffuses into the proliferative 
zone along a concentration gradient. This gradient is thought to guide the orientation of the 
proliferative chondrocytes. 
The stem-like cells in the resting zone have a defined proliferative capacity, which is 
gradually exhausted and leads to fusion of the growth plate. Thus, the epiphyseal fusion 
process seems to be the result and not the cause of growth cessation at the moment of 
skeletal maturation. Accordingly, the term “growth plate senescence” has been introduced 
by Nilsson and Baron (2004). In this context, Stevens et al. (1999) demonstrated in 
transplantation experiments the dependence of the growth rate on the age of the donor 
animal, not that of the recipient. This finding indicates that the programmed senescence is 
not caused by hormonal or other systemic mechanisms but is intrinsic to growth plate cells 
themselves. In further investigations Gafni et al. (2001) showed that senescence is a function 
of proliferation: After systemic treatment with dexamethasone, a glucocorticoid that slows 
chondrocyte proliferation, the treated growth plates showed a delay in senescent decline of 
the growth rate, and the epiphyseal fusion occurred later.  
 
2.2 The proliferative zone 
After entering the cell cycle the cells begin to proliferate. During mitosis the cells divide in 
the horizontal axis followed by a rotation and finally the arrangement in the vertical axis 
forming the characteristic columns parallel to the longitudinal axis of the bone (Aszodi et al., 
2003). These columns are separated from each other by matrices with large amounts of 
collagen Type II. Each column contains 10 to 20 cells, depending on the mitotic activity of 
the chondrocytes. In the proximal portion of each column, multiple mitotic figures can be 
observed. It is interesting that the achromatic figure spindles are arranged parallel to the 
long axis of the bone and that the chondrocytes migrate after division so that eventually the 
daughter cells are lined in the longitudinal axis (Trueta & Morgan, 1960; Stevenson et al., 
1990). The proliferating zone is the only region in the growth plate where chondrocytes have 
relevant mitotic activity. Biochemically, in this zone the high oxygen content is noteworthy, 
as well as the high glycogen content and increased mitochondrial ATP production in 
chondrocytes (Brighton & Heppenstall, 1971). 
 
2.3 The hypertrophic zone 
After 5-10 mitotic cycles the chondrocytes lose their proliferative capacity and enter the so-
called G0 phase for further differentiation. After passing a prehypertrophic stage 
chondrocyes enter a hypertrophic differentiation stage, which in the growth plate 
unidirectionally leads to terminal differentiation. During this process the chondrocytes 
increase their volume, especially in their longitudinal diameter, about 5- to 10-fold. In this 
way, hypertrophic differentiation makes an important contribution to longitudinal growth. 
Furthermore, the hypertrophic cells synthesize high amounts of extracellular matrix 
components, especially collagen Type X (Hunziker et al., 1987; Breur et al., 1991). In 
comparison to the resting zone and the proliferative zone, the hypertrophic zone is 
 
characterized by a distinctly different extracellular matrix composition: The synthesis of the 
collagens Type II, IX and XI is dramatically reduced, whereas the production of collagen 
Type X increases. In fact, collagen Type X is only expressed in this zone of the growth plate 
and hence, it is considered to be a specific marker for chondrocytic hypertrophy. 
Furthermore, hypertrophic chondrocytes show a significant increase of intracellular calcium 
concentration. Intracellular calcium is essential for the production of release vesicles (Wang 
& Kirsch, 2002), which are rich in several types of Ca2+-binding annexins which promote 
Ca2+ uptake by these vesicles (Kirsch et al., 2000; Wang et al., 2003). Calcium phosphate, 
hydroxyapatite, phosphatases such as alkaline phophatase, and metalloproteinases are 
secreted via exocytosis, thus driving proteolytic remodelling and mineralization of the 
surrounding matrix (Lewinson & Silbermann, 1992; Vu et al., 1998). Moreover, the 
hypertrophic chondrocyte is a crucial master regulatory cell with an active metabolism. It 
prepares the matrix for calcification and vascularization (Forriol & Shapiro, 2005). In this 
context the expression of Vascular Endothelial Growth Factor (VEGF) by hypertrophic 
chondrocytes is of special interest for the initiation of the terminal ossification process. 
 
2.4 The invasive zone 
The expression of VEGF attracts invading blood vessels and, concomitantly, osteoblastic 
cells (Gerber et al., 1999). After vascularization of the mineralized cartilaginous matrix, the 
matrix is degraded by immigrant chondroclasts/ osteoclasts (Lewinson & Silbermann, 1992; 
Vu et al., 1998). The main part of the longitudinal septa (up to 80%) within the hypertrophic 
cartilage is rapidly resorbed behind the invading blood vessels, whereas the remaining septa 
serve as scaffolds on which osteoblasts deposit bone matrix (Salle et al., 2002). Finally, 
triggered by caspases, the hypertrophic chondrocytes undergo apoptosis or are resorbed 
(Gibson, 1998; Salvesen & Dixit, 1997). 
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 Fig. 2. The growth palte is a well organized structure between the epihysis and the 
diaphysis of the long bones. The chondrocytes are arranged according to there proliferation 
and differentiation stage with small round shaped cells in the resting zone, flat, proliferating 
cells in the proliferatve zoe and great cells in the hypertrophic zone. In the invasive zone 
vessels grow in and give rout for the final ossification (HE and transmission electron 
microscopical images). 
 
3. Molecular Regulation of Endochondral Ossification 
The complex interplay between chondrocyte proliferation and differentiation, which is 
responsible for the characteristic morphological features of the growth plate, is highly 
orchestrated by the interaction of multiple systemic hormones and paracrine factors, which 
finally lead to changes in gene expression of the chondrocytes in the growth plate. The 
fundamental importance of endochondral ossification in long bone growth and 
development as well as in repair mechanisms of the skeleton is one reason for the increasing 
interest in the molecular factors that regulate this critical pathway. This section describes the 
latest insights into the regulation of chondrocyte proliferation and differentiation within the 
growth plate and focusses on molecules that play key roles in embryology and 
development. The description represents a choice of some important molecules without any 
claim to be exhaustive. A more prescise review of the different pathways involved in growth 
plate with respect to its potential relevance for tissue engineering is given elsewhere 
 
(Brochhausen et al. 2009). Table 1 summarizes the most important characteristics and effects 
of the signalling molecules and growth factors, which are described in detail below. 
 
3.1 Bone Morphogenetic Proteins 
Bone Morphogenetic Proteins (BMPs) represent a group of well known growth factors of the 
Transforming Growth Factor superfamily (TGF-beta). They were first identified and 
described by their capacity to stimulate ectopic cartilage and bone formation (Wozney, 
1989). On this basis, BMP’s represent a prime example of the high potential of growth 
factors for tissue engineing strategies. Today their important functional role in osteogenesis 
and chondrogenesis is well established. In early fetal development BMPs play important 
roles in the aggregation of mesenchymal cells during limb bud formation (Pizette & 
Niswander, 2000). In addition, BMPs influence the complex mechanisms in developing bone 
at later stages of skeletal development. The cellular effects of BMPs are mediated by two 
type I receptors, namely BMPRIA and BMPRIB, which heterodimerize with a type II 
receptor (BMPRII). The expression of BMPRIB was described by Zou et al. (1997) in early 
embryological development during mesenchymal cell condensations, which gives evidence 
that this receptor is involved in early bone and cartilage formation. The receptor BMPRIA 
could be detected in prehypertrophic chondrocytes (Zou et al., 1997). The differential 
expression of these receptors indicates the involvement of BMP-related pathways in 
different steps of bone and cartilage development. In this context it is of interest that BMPs 
have different expression patterns within bone and cartilage: BMP2, -3, -4, -5, and -7 are 
expressed in the perichondrium. BMP2 and -6 are expressed in hypertrophic chondrocytes 
and BMP7 is expressed in proliferating chondrocytes. 
BMPs are integrated in the Ihh-PTHrP (Indian hedgehog-parathyroid hormone-related 
peptide) signalling loop. They are capable of inducing the expression of Ihh and, hence, 
increase chondrocyte proliferation (Grimsrud et al., 2001). Furthermore, BMP pathways 
inhibit FGF signalling by constraining the expression of FGFR1 (fibroblast growth factor 
receptor 1) (Yoon et al., 2006). Within the growth plate a concentration gradient of BMP may 
be a key feature responsible for spatial regulation of chondrocyte proliferation and 
differentiation (Nilsson et al., 2007). 
Regarding tissue engineering strategies it is not surprising that recombinant human BMP’s 
have already found their way into clinical practice for the treatment of critical sized bone 
defects. To further optimize the use of these factors in tissue engineering the identifcation 
and synthesis of well-defined carriers with suitable BMP release profiles is necessary as 
described by Bessa et al. (2008). A detailed description of the physiological function of the 
different BMP’s during bone development is given by Kronenberg (2003), Forriol and 
Shapiro (2005). 
 
3.2 Fibroblast Growth Factor-signalling  
Fibroblast Growth Factors (FGFs) represent a superfamily of peptide growth factors 
synthesized by a variety of human and animal cells and act in a paracrine manner on their 
target cells. The cellular effects are mediated by plasma membrane tyrosine kinase receptors. 
The 22 distinct human FGFs are involved in diverse biological processes. In this context, a 
temporal selectivity in their expression is involved in the regulation of these pathways: the 
expression of FGF3, FGF4, FGF8 and FGF17 is restricted to embryonic tissue, whereas other 
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FGFs play significant roles not only in developmental processes but also in the biology of 
mature tissues (Jones, 2008). A further dicrimination of the effects in the FGF-related 
pathways is given by the mediation via four different types of FGF receptors (FGFR).  
Regarding skeletal development FGF1, 2, 17, and 19 are the predominant FGF members 
present in developing human cartilage (Krejci et al., 2007). In the early stage of 
endochondral bone formation multiple FGF’s as well as FGFR2 are expressed in condensing 
mesenchymal cells, which is thought to stimulate SOX9 expression (Murakami et al., 2000). 
FGFR3 is expressed by proliferating chondrocytes in the human growth plate, whereas 
FGFR1 is located in prehypertrophic and hypertrophic chondrocytes. Additionally, FGFR2 
can be detected on perichondral cells. Each of these receptors has distinct roles in bone 
development. At the moment FGFR3 is best understood: FGFR3 inhibits the proliferation of 
growth plate chondrocytes, especially by down-regulating Ihh expression in hypertrophic 
chondrocytes. Hence, FGF signalling shortens the proliferative columns. Furthermore, FGFs 
decelerate chondrocytic terminal differentiation. Thus, they decrease matrix synthesis and 
consequently delay hypertrophy of the growth plate chondrocytes (Kato & Iwamoto, 1990). 
FGF18 is expressed in the perichondrium and by an activation of FGFR3 this factor is 
thought to regulate skeletal vascularization (Liu et al., 2007). The crucial role of FGFR3-
mediated pathways in skeletal development is illustrated by the fact that a specific mutation 
in FGFR3 causes achondroplasia, the most common dwarfism in humans (Bellus et al., 1995; 
Shiang et al., 1994). A comprehensive overview of FGF and its functions during skeletal 
development is given by Olsen et al. (2000), Kronenberg (2003) as well as by Forriol and 
Shapiro (2005).  
 
3.3 Parathyroid Hormone-related Peptide (PTHrP) and Indian hedgehog (Ihh) 
PTHrP is a peptide which shares a receptor with the parathyroid hormone and has at its 
amino-terminus the identical 13 aminoacids as in the hormone itself. However, in contrast to 
the hormone PTHrP is detectable in many adult and developing tissues (Ingleton and 
Danks, 1996). Functionally, PTHrP is much more related to developmental growth factors 
such as FGF or TGF-beta than to a hormone. The identification of the PTHrP/Ihh feedback 
loop led to a major advancement in our understanding of growth plate regulation since it 
became clear that this pathway regulates the entry of chondrocytes into the hypertrophic 
phase of growth (Alvarez et al. 2003). The interplay between PTHrP and Ihh determines the 
moment when the chondrocytes leave the proliferative zone and enter the transition to 
hypertrophic chondrocytes. Perichondral cells and chondrocytes in the periarticular 
perichondrium synthesize PTHrP. This protein diffuses toward the prehypertrophic zone 
where cells have a high expression level of PTH/PTHrP receptors. After binding, PTHrP 
inhibits further differentiation to hypertrophic chondrocytes and keeps the chondrocytes in 
the proliferative stage (Lee et al., 1996). In the moment when the diffusion distances from 
the PTHrP-producing cells become too long, the effector cells are no longer sufficiently 
stimulated by PTHrP, which results in a delay of proliferation and the synthesis of Ihh, a 
member of the hedgehog family. Indian hedgehog is not only important in embryological 
development but also in the regulation of the growth plate. In this context Ihh is synthesized 
by prehypertrophic chondrocytes. As a consequence, the rate of chondrocyte proliferation 
increases and, by mechanisms that are still not fully understood, Ihh stimulates the 
production of PTHrP at the bone ends. Furthermore, by action of Ihh perichondral cells 
convert into osteoblasts and thus, enhance the formation of the bone collar. The essential 
 
role of Ihh in the postnatal integrity of the growth plate and endochondral ossification was 
clearly demonstrated by Maeda et al. (2007).  
 
3.4 Vascular Endothelial Growth Factor  
In the final ossification of the growth plate which leads to the formation of new bone the 
vascularisation of hypertrophic cartilage represents a crucial step. Thus, it is important that 
hypertrophic chondrocytes of the growth plate produce and secrete Vascular Endothelial 
Growth Factor (VEGF), one of the most potent angiogenetic factors (Gerber et al., 1999). 
VEGF in turn stimulates the proliferation and migration of endothelial cells. It enhances the 
formation of blood vessels in the hypertrophic zone of the growth plate and with this paves 
the way for ingrowth of osteoblasts, thus leading to ossification. Furthermore, the 
vascularization of the calcified cartilage within the invasive zone is essential for the 
resorption of chondrocytes by chondroclasts. Experimental data were able to demonstrate 
that the absence of VEGF causes profound disturbances in the architecture of the growth 
plate and affects significantly the longitudinal growth. In the absence of VEGF calcified 
cartilage persists as a result of a decrease in the recruitment and differentiation of 
osteoblasts and /or chondroclasts. As a morphological consequence a widening of the 
hypertrophic region and diminished trabecular bone formation could be observed as a 
result of the reduced elimination of terminally differentiated chondrocytes (Gerber et al., 
1999). Thus, VEGF-mediated capillary invasion is an essential signal that triggers cartilage 
remodelling and hence influences growth plate morphogenesis. Interestingly, hypertrophic 
chondrocytes also express receptors for VEGF, which leads to the hypothesis that this factor 
could have an autocrine function in these cells (Carlevaro et al., 2000). In addition to VEGF, 
ligands for the tyrosine kinase receptor Tie2 are further key regulators of angiogenesis and 
post-angiogenic blood vessel maturation (Asahara T, 1998, Suri C et al., 1996). The 
investigations of Horner et al. (2001) revealed the expression and spatial distribution of 
angiopoietin-1 and -2 (Ang-1 and Ang-2), the ligands for the endothelial receptor Tie-2 in 
the human growth plate. This group described Ang-1 and Ang-2 as an important regulator 
in the orchestration of neovascularization in the growth plate. In this context, Ang-1 and 
Ang-2, which were expressed by hypertrophic chondrocytes of the growth plate, seemed to 
modulate the effects of VEGF (Horner et al., 2001). The fundamental role of VEGF during 
long bone development is reviewed in detail by Ballock and O’Keefe (2003).  
 
3.5 Sox transcription factors 
Sox proteins are a member of the High-Mobility-Group (HMG) superfamily, which 
represents DNA-binding proteins, whose sequence is at least 50% identical with the 
sequence of the HMG domain of the sex-determining region located on the Y chromosome 
of human and other mammals (Sinclair et al., 1990). This relation is responsible for the name 
of the Sox protein family (Wegner, 1999). During long bone development Sox9 is critically 
involved in several stages during the developmental processes. In early embryological 
development Sox9 is required for the aggregation of mesenchymal cells (Bi et al., 1999). Sox5 
and Sox6, two other members of the Sox family, are coexpressed with Sox9 in 
chondroprogenitor cells and there is strong evidence that these genes are clearly needed for 
the differentiation of the chondrocytic lineage (Lefebvre et al., 1998; Akiyama et al., 2002). 
Furthermore, Sox9 is necessary for the expression of various extracellular matrix 
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Furthermore, Sox9 is necessary for the expression of various extracellular matrix 
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components, especially the collagen Types II, IX, XI as well as aggrecan (Bi et al., 1999; 
Lefebvre and de Crombrugghe, 1998). At later stages of development, the presence of Sox9, 
partly mediated by Sox5 and Sox6, is essential for chondrocyte proliferation and the 
alignment of proliferative clones into columns parallel to the longitudinal axis of the 
developing bone, indicating their important role in the proliferative zone of the growth plate 
(Akiyama et al., 2002). This fact is further ilustrated by the fact that the expression of the 
Sox5, Sox6, and Sox9 genes is completely turned off in hypertrophic chondrocytes (Lefebvre 
et al., 1998). Functionally, in the proliferative zone of the growth plate Sox9 prevents the 
transition of proliferating chondrocytes into hypertrophic chondrocytes, and is thus 
involved in the control of subsequent endochondral ossification (Akiyama et al., 2002). 
Furthermore, Zehentner et al. (1999) provided evidence that BMPs are also modulated by 
the expression of Sox9. With the help of transducing experiments Hardingham et al. (2006) 
demonstrated the critical role of Sox9 in chondrogenesis of isolated human articular 
chondrocytes. Regarding possibile tissue engineering strategies for cartilage, Khan et al. 
(2009) concluded that chondroprogenitors maintain SOX9 expression during extended 
monolayer culture and further retain chondrogenic potential. These findings demonstrate 
that the sox transcription factors not only play a crucial role in endochondral ossification but 
also in establishing the phenotype of articular cartilage both in vivo and in vitro, indicating 
that the regulation of the growth plate represents a suitable model to target potential 
signalling molecules and growth factors for cartilage tissue engineering. 
 
3.6 Runx2 
Runx2 (also known as Cbfa1) is another important transcription factor of the Runt-domain 
family (Ito, 1999). Runx2 is expressed during condensation of mesenchymal cells in early 
bone development and later in osteoblasts, but also in hypertrophic chondrocytes (Ducy et 
al., 1997; Inada et al., 1999; Kim et al., 1999; Otto et al., 1997). The analyses of Runx2 deficient 
mice gave evidence for the crucial functions of Runx2 during skeletal development: This 
transcription factor is firstly required for the differentiation of mesenchymal progenitor cells 
into osteoblasts. Later on in the growth plate of the long bones Runx2 enhances chondrocyte 
terminal differentiation (Inada et al., 1999; Kim et al., 1999) opening up the way for 
subsequent ossification. In Runx2-deficient mice, no endochondral and no intramembranous 
bone formation is present due to an arrest in osteoblast differentiation (Otto et al., 1997; 
Komori et al., 1997). In such mice, most bones either lack, or have reduced numbers of 
hypertrophic chondrocytes. In addition, hypertrophic chondrocytes fail to mineralize their 
matrix and have reduced or undetectable expression levels of osteotypical genes, such as 
osteopontin and MMP-13 (Takeda et al., 2001; Ueta et al., 2001). Thus, Runx2 is required for 
the differentiation of mesenchymal progenitor cells into osteoblasts. Furthermore, in the 
growth plate of long bones, this transcription factor enhances chondrocyte terminal 
differentiation (Inada et al., 1999; Kim et al., 1999) and is therefore a crucial factor for the 
definitive formation of trabecular bone. 
 
 
 Fig. 3. Schematic depiction of the regulation of the growth plate with stimulating molecules 
(green arrows) and inhibitory molecules (red lines). 
 
3.7 Prostaglandin E2 
Prostaglandin E2 (PGE2) is a metabolite of the arachidonic acid cascade, an evolutionary 
highly conserved familiy of lipid mediators. Prostaglandins are involved in numerous 
physiological and pathophysiological mechanisms, as well as in the regulation of 
developmental processes. In the latter context, PGE2 also plays a significant role in skeletal 
development. In osteoblast-like cells, endogenous PGE2 was shown to affect proliferation 
and differentiation by stimulation of DNA synthesis and alkaline phosphatase activity 
(Igarashi et al., 1994). Furthermore, PGE2 influences the differentiation of chondrocytes as 
previously shown for the chondrocyte cell line RCJ3.1C5.18 (Lowe et al. 1996) and for rat 
growth plate chondrocytes (Schwartz et al. 1998, O’Keefe et al., 1992, Brochhausen et al., 
2006). In addition to such findings in cell culture, the physiological role of prostaglandins 
was clarified by its stimulating effect on bone formation and increase in bone mass after 
systemic administration of PGE2 to infants (Ueda et al., 1980) and animals (Suponitzki & 
Weinreb, 1998). Interestingly, also local administration of PGE2 resulted in osteogenesis in 
situ (Yang et al., 1993, Marks & Miller, 1988). The cellular effects of PGE2 are mediated by 
the binding to transmembranal G protein-coupled receptors. Four different EP receptors are 
known, which are linked to different intracellular signal transduction pathways (Narumiya 
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et al., 1999). The EP1 receptor is coupled to intracellular Ca2+ mobilization, while the EP2 
and EP4 receptors increase intracellular cAMP accumulation. By contrast, EP3 inhibits 
intracellular cAMP accumulation. Regarding bone formation and bone resorption the EP4 
receptor has been shown to be essential in terms of PGE2 action in bone (Yoshida et al., 
2002). In this respect the critical involvement of EP4 receptor in fracture healing was 
demonstrated very recently (Yoshida et al., 2002, Xie et al., 2009). Furthermore, EP2 and EP4 
receptors were shown to be required for PGE2-dependent chondrocyte differentiation 
(Miyamato et al., 2003).  
Despite their obvious role in bone and cartilage metabolism, prostaglandins are not in the 
main focus regarding potential tissue engineering strategies of bone and cartilage.  
 
Name Substance class Receptors Effect Reference 
BMP Protein growth 
factor 
BMPRI-A, 
BMPRI-B 
Cartilage & 
bone 
formation 
Grimsrud et al. 
(2001), Pizette & 
Niswander (2000) 
FGF peptide growth 
factor 
FGFR1, 
FGFR2, 
FGFR3 
Mesenchymal 
condensation, 
Osteogenic 
differentiation 
Kronenberg (2003), 
Hassan et al. (2007) 
Krejci et al. (2007) 
PTHr
P 
Signalling 
peptide 
G-protein GS 
and Gq 
receptors 
Chondrocyte 
proliferation 
Lee et al. (1996) 
Ihh Signalling protein Patched-1, 
Smo 
Chondrocyte 
proliferation 
Kronenberg (2003) 
VEGF Protein growth 
factor 
VEGF-R Vascularizatio
n, ingrowth of 
osteobalsts & 
chondroblasts 
Gerber et al. (1999) 
Sox Transcription 
factor 
DNA-
binding 
Chondrocyte 
differentiation 
& 
proliferation 
Lefebvre et al. (1998) 
Akiyama et al. (2002) 
Runx
2 
Transcription 
factor 
DNA-
binding 
Matrix 
mineralization
, chondrocyte 
differentiation 
Inada et al. (1999) 
Kim et al. (1999), 
Takeda et al. (2001), 
Ueta et al. (2001) 
PGE2 Lipid mediator G-protein 
receptors, 
EP1, EP2, 
EP3, EP4 
Chondrocyte 
proliferation, 
bone 
formation 
Brochhausen et al. 
(2006) 
Xie et al. (2009) 
Table 1. Summary of important growth factors and signalling molecules with relevant 
impact for the regulation of proliferation and differenzation of growth plate chondrocytes. 
 
4. Experimental Setup 
A principal aim of our research efforts was to develop an integrated release-system in an 
oriented scaffold for cartilage tissue engineering. Regarding the scaffold, one goal was to 
imitate the physiological fibre orientation of articular cartilage to achieve a topographically 
beneficial microenvironment. Articular cartilage represents a highly organized tissue not 
 
only at the cellular level, but also at the level of extracellular matrix components. Based on 
the spatial distribution, the morphological characterization and the biochemical activity of 
cells three zones are distinguishable in the articular cartilage (fig. 4): the superficial zone 
with flat aligned chondrocytes and perpendicularly arranged fibres, the middle zone with 
clusters of round shaped chondrocytes in a scaffold of parallel aligned collagen fibres and 
the deep zone with calcified cartilage.  
 
 Fig. 4. Histomorphology of articular cartilage of the rat (HE, x200) with schematic depiction 
of the fibre arrangement.  
 
Reviewing the previously described signalling molecules, there are several reasons for the 
use of PGE2 in cartilage tissue engineering: First of all several in vitro and in situ data 
demonstrate an important role for PGE2 in cartilage development. Furthermore, this 
molecule, its metabolism, biological effects and possible side effects are already well 
understood and investigated. Finally, this substance is already on the market since decades, 
and is thus available in pharmaceutical quality and for a price less expensive than many of 
the modern developments. Since PGE2 has a short half-life, which ranges under 
physiological conditions between 30 seconds in the cardiovascular system and 35 minutes in 
amniotic fluid (Bygdeman 2003, Ghodgaonkar et al. 1979) we established a release system 
for this molecule as an important prerequisite for its potential use in tissue engineering 
strategies. As release sytem we developed poly-D,L-lactide-co-glycolide (PLGA) 
microspheres, which were originally designed for the expansion of chondrocytes (Gabler et 
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of the fibre arrangement.  
 
Reviewing the previously described signalling molecules, there are several reasons for the 
use of PGE2 in cartilage tissue engineering: First of all several in vitro and in situ data 
demonstrate an important role for PGE2 in cartilage development. Furthermore, this 
molecule, its metabolism, biological effects and possible side effects are already well 
understood and investigated. Finally, this substance is already on the market since decades, 
and is thus available in pharmaceutical quality and for a price less expensive than many of 
the modern developments. Since PGE2 has a short half-life, which ranges under 
physiological conditions between 30 seconds in the cardiovascular system and 35 minutes in 
amniotic fluid (Bygdeman 2003, Ghodgaonkar et al. 1979) we established a release system 
for this molecule as an important prerequisite for its potential use in tissue engineering 
strategies. As release sytem we developed poly-D,L-lactide-co-glycolide (PLGA) 
microspheres, which were originally designed for the expansion of chondrocytes (Gabler et 
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a., 2007). Polylactide and its polymers are well established as drug release systems and are 
already in clinical use. Some examples for polylactide based release systems which are 
already in clinical application or hich are used in anmimal models are presented in Table 2, 
indicating that various substances can be integrated in corresponding systems. Thus, the 
polymer used in our experiments has also been shown to be could also be suitable for the 
integration and controlled release of further potential signalling moecules or growth factors. 
For the analyses of the PGE2 levels a novel sample preparation procedure was developed 
based on a previously published gas chromatography tandem mass spectrometry (GC-
MS/MS) method for prostaglandin detection (Schweer et al., 1994). The modification of this 
method wich is demonstrated in detail elswere (Watzer et al., 2009, Brochhausen et al., 2009) 
was necessary to determine the incorporated PGE2 levels. 
The combination of two different material approaches for scaffold and release sytems was 
given by the idea to create a veritable toolbox which permits the use of different factors in 
the same three-dimensional scaffold material combined with a systematic analysis of their 
effects. 
 
Active 
Agent 
Release systeme Indication Reference 
TGF-beta 1 PLGA (scaffold) Cartilage/bo
ne grwoth 
Gombotz et al. (1994) 
BMP PLGA (scaffold) Bone growth Ferguson et al. (1987), 
Johnson et al. (1988) 
VEGF PLGA-PEG 
(microspheres) 
Angiogenesis King & Patrick (2000) 
PGE1 Lipid-microspheres Vasodilatatio
n 
Kanamaru et al. 
(1998) 
Table 2. Summary of active agents integrated in a PLGA related release-system, which are 
either used in animal models or already in clinical application. 
 
5. Research 
5.1 Scaffold design 
From the biomaterial point of view the basis for the scaffold system was the development of 
a processing route for a material with similar structural, biochemical and mechanical 
properties as native articular cartilage. The basic approach and methodology for the 
synthesis route is based on a directional freezing technique which can be further combined 
with an electrolytic process (Zehbe et al., 2005). For this purpose, a gelatin solution was 
exposed to an electric field which leads to an arrangement of the fibres along the gas bubble 
formation. The container with the gelatin solution was positioned on the cold side of a 
peletier element. Thus, variation of the applied temperature was possible. A detailed 
description of the combination process which adapts an electrolytic decomposition process 
of the gelatin solution to introduce another pore fraction prior to freezing is precisely 
decribed in Zehbe et al. (2004, 2005). Freezing led to a stabilization of the fibre arrangement 
along the direction of ice crystal formation. After complete freezing, the sample was freeze 
dried to remove the ice crystals. Since a non-cross linked gelatin-based sample would 
rapidly dissolve under the fluid conditions in vitro or in vivo, the material was finally cross-
 
linked to guarantee chemical stability of the material. As a result, a porous network was 
achieved after complete removal of the formed ice crystals. 
Interestingly, the degree of directionality of the pores as well as the pore size is dependent 
on the freezing temperature, the ion content and the gelatin concentration. Thus, scaffolds 
with suitable directional pore channels could be synthesized at lower freezing temperatures 
without additional ions, while scaffolds with larger, non-directional pores could be made 
using higher freezing temperatures and elevated ion contents (fig 5a). In addition, based on 
this original scaffold processing route, we have introduced a hydroxyapatite layer to mimick 
the subchondral bone and address the potential application in tissue engineered-based 
treatment of deep cartilage defects (fig 5b). 
Furthermore, we integrated in this scaffold drug release components in the form of PLGA-
microspheres, which themselves were further enhanced by the integration of an active agent 
to meet so-called 3rd generation tissue engineering requirements. 
 
 Fig. 5. X-ray tomographic slice representations of scaffolds with varying pore-channel 
networks (a) and sliced representation of a scaffold featuring hydroxyapatite as bone-like 
layer (b) (adapted from Zehbe et al., 2007). 
 
5.2 PLGA- release system for prolonged PGE2 release 
As already mentioned above, the possible use of PGE2 is highly limited due to its short half-
life under physiological conditions. Therefore, for tissue engineering strategies this molecule 
should be used in the form of a release-system to guarantee a prolonged bioavailability. 
With respect to the microsphere scaffold modification we adapted an emulsion-based 
synthesis pathway which is described in detail by Brochhausen et al. (2007, 2009). In these 
protocols the microspheres were synthesized using a co-solvent emulsification method. The 
PLGA (Resomer RG859SR, Boehringer Ingelheim) used in our experiments had a lactide-
glycolide-ratio of 85:15, a residual monomer content of < 2.0 % and an inherent viscosity of 
2.5 - 3.5 dl/g. In the first step, 0.1 g PLGA granules were dissolved in 1.0 CHCl3. Then, PGE2 
was dissolved in hexauoroisopropanol (HFIP) in a concentration of 1.0 mg/ml. The PLGA 
solution was mixed with the PGE2 solution giving the following composition: 0.1 g PLGA, 
3.5 µg PGE2, 1.0 ml CHCl3 and 3.5 µl HFIP. To allow the complete removal of the organic 
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of the gelatin solution to introduce another pore fraction prior to freezing is precisely 
decribed in Zehbe et al. (2004, 2005). Freezing led to a stabilization of the fibre arrangement 
along the direction of ice crystal formation. After complete freezing, the sample was freeze 
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linked to guarantee chemical stability of the material. As a result, a porous network was 
achieved after complete removal of the formed ice crystals. 
Interestingly, the degree of directionality of the pores as well as the pore size is dependent 
on the freezing temperature, the ion content and the gelatin concentration. Thus, scaffolds 
with suitable directional pore channels could be synthesized at lower freezing temperatures 
without additional ions, while scaffolds with larger, non-directional pores could be made 
using higher freezing temperatures and elevated ion contents (fig 5a). In addition, based on 
this original scaffold processing route, we have introduced a hydroxyapatite layer to mimick 
the subchondral bone and address the potential application in tissue engineered-based 
treatment of deep cartilage defects (fig 5b). 
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5.2 PLGA- release system for prolonged PGE2 release 
As already mentioned above, the possible use of PGE2 is highly limited due to its short half-
life under physiological conditions. Therefore, for tissue engineering strategies this molecule 
should be used in the form of a release-system to guarantee a prolonged bioavailability. 
With respect to the microsphere scaffold modification we adapted an emulsion-based 
synthesis pathway which is described in detail by Brochhausen et al. (2007, 2009). In these 
protocols the microspheres were synthesized using a co-solvent emulsification method. The 
PLGA (Resomer RG859SR, Boehringer Ingelheim) used in our experiments had a lactide-
glycolide-ratio of 85:15, a residual monomer content of < 2.0 % and an inherent viscosity of 
2.5 - 3.5 dl/g. In the first step, 0.1 g PLGA granules were dissolved in 1.0 CHCl3. Then, PGE2 
was dissolved in hexauoroisopropanol (HFIP) in a concentration of 1.0 mg/ml. The PLGA 
solution was mixed with the PGE2 solution giving the following composition: 0.1 g PLGA, 
3.5 µg PGE2, 1.0 ml CHCl3 and 3.5 µl HFIP. To allow the complete removal of the organic 
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solvents by evaporation, the resulting solution was stirred over night in 0.5 % polyvinyl 
alcohol at 300 rpm with the help of a multi-position magnetic stirrer (RO 15 power Ikamag, 
IKA, Germany) according to the adaption of a previously described method (Gabler et al., 
2007). Finally, the resulting microspheres were washed in sterile deionized water. 
The characterization of the microspheres especially with respect to their size distribution 
was performed according to a protocol developed in our research group: In brief, SEM-
images showing approximately 50 to 100 well dispersed microspheres were imaged top 
down and were then analyzed with the software ImageJ according to Gabler et al. (2007). In 
addition, the degradation changes regarding mass loss, pH-shift and the morphological 
changes of the microspheres in cell culture medium were documented over a timeframe of 
up to 100 days. Regarding the release profile we were able to show the kinetics of PGE2 
release over a period of 154 hours as measured by gas chromatography-mass spectroscopy 
(GC-MS/MS) and mass spectroscopy (Brochhausen et al.,2009). For this purpose the method 
of Schweer et al. (1994) was adapted. An important advantage of this method is that the 
structurally and thus functionally intact molecule could be detected even at very low 
concentrations. As a result of our analyses, we were able to determine reliably the amount of 
incorporated PGE2 in the PLGA microspheres. Interestingly, the stability of PGE2 was pH 
dependent: Strong acidic or basic environments reduced the half-life from 300 hours (pH 2.6 
- 4.0) to below 50 hours at pH 2.0 or pH 8.8. Furthermore, we showed that the half-life of 
incorporated PGE2 is highly temperature dependent (fig. 6). Thus, the half life could be 
increased from 70 days at 37 °C to 300 days at 8 °C. In our kinetic study we demonstrated a 
gradual concentration increase of PGE2 in DMEM over the first 13 h, followed by a 
concentration plateau for 35 h and a slight decline of the PGE2 concentration after the 48 h 
time point.  
 
 Fig. 6. pH dependent (a) and temperature dependent stability of PGE2 (b), graphs adapted 
from Watzer et al., 2009. 
 
For the used PLGA-type with a lactide-glycolide-ratio of 85:15 we hypothesized that the 
PGE2 is primarily released from the outer shell of the microsphere as depicted in figure 7. 
Our image shows a microsphere after degradation for 80 days, as well as a superimposed 
graph of the kinetic experiments. After 80 days in cell culture medium the interior of the 
sphere is highly degraded, while the shell is almost intact. Further analysis with SR-µCT 
 
revealed that the microspheres consist of a porous shell and a compact core. These findings 
could be confirmed by scanning electron microscopy (SEM) and atomic force microscopy 
(AFM) which clearly showed the internal and external structure of the microspheres with a 
distinct nanostructure of the polymeric phase and both nano- and micro-porosity (Watzer et 
al., 2009). Thus, the rapid increase of PGE2 could be the result of the release out of the 
porous shell, whereas the later PGE2 values could be the result of the release out of the core. 
Regarding the degradation of the microspheres we hypothesized that the slow erosion of the 
surfaces results in a semi-permeable membrane which delays the release of degradation 
products and thus results in autocatalytic processes, amplifying the degradation inside the 
material (Heidemann et al., 2002, Maspero et al., 2002, Gabler et al., 2007). 
 
 Fig. 7. PGE2 release profile from PLGA microspheres and proposed release mechanism 
derived from SEM investigations. Initial release from the outer shell (a) and sustained 
release from the core after more than 160 h (b). 
 
For the combined drug-release-scaffold system PGE2-loaded microspheres were added to 
the gelatin solution and stirred until the gelatin gelled. By this procedure sedimentation of 
the spheres could be prevented so that a homogeneous distribution of microspheres could 
be reached without negatively affecting the casting of the gelatin in the freezing apparatus. 
After the freezing process, the microsphere-modified frozen gelatin samples were freeze 
dried and chemically cross linked as described above. We analysed the distribution of the 
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gradual concentration increase of PGE2 in DMEM over the first 13 h, followed by a 
concentration plateau for 35 h and a slight decline of the PGE2 concentration after the 48 h 
time point.  
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Our image shows a microsphere after degradation for 80 days, as well as a superimposed 
graph of the kinetic experiments. After 80 days in cell culture medium the interior of the 
sphere is highly degraded, while the shell is almost intact. Further analysis with SR-µCT 
 
revealed that the microspheres consist of a porous shell and a compact core. These findings 
could be confirmed by scanning electron microscopy (SEM) and atomic force microscopy 
(AFM) which clearly showed the internal and external structure of the microspheres with a 
distinct nanostructure of the polymeric phase and both nano- and micro-porosity (Watzer et 
al., 2009). Thus, the rapid increase of PGE2 could be the result of the release out of the 
porous shell, whereas the later PGE2 values could be the result of the release out of the core. 
Regarding the degradation of the microspheres we hypothesized that the slow erosion of the 
surfaces results in a semi-permeable membrane which delays the release of degradation 
products and thus results in autocatalytic processes, amplifying the degradation inside the 
material (Heidemann et al., 2002, Maspero et al., 2002, Gabler et al., 2007). 
 
 Fig. 7. PGE2 release profile from PLGA microspheres and proposed release mechanism 
derived from SEM investigations. Initial release from the outer shell (a) and sustained 
release from the core after more than 160 h (b). 
 
For the combined drug-release-scaffold system PGE2-loaded microspheres were added to 
the gelatin solution and stirred until the gelatin gelled. By this procedure sedimentation of 
the spheres could be prevented so that a homogeneous distribution of microspheres could 
be reached without negatively affecting the casting of the gelatin in the freezing apparatus. 
After the freezing process, the microsphere-modified frozen gelatin samples were freeze 
dried and chemically cross linked as described above. We analysed the distribution of the 
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microspheres by high resolution X-Ray tomography as described in detail in the chapter by 
Zehbe et al. in this book. 
 
5.2 Chondocyte isolation and Cell Seeding of Scaffolds 
For the cell culture experiments with the release-scaffold system bovine chondrocytes were 
used. For this purpose, fetlock joints of 3-4 months old calves were obtained directly after 
slaughter and processed under aseptic conditions. Articular cartilage chondrocytes were 
harvested aseptically from dissected flakes of the full thickness cartilage. After harvesting 
the cartilage flakes were washed twice for 15 min with Tyrode’s balanced salt solution 
(TBSS) containing penicillin, streptomycin and amphotericin B. The cartilage flakes were 
then predigested with 1 mg/mL of pronase (Roche Diagnostics GmbH, Mannheim, G) on a 
magnetic stirrer at 37°C for 2 h, followed by washing with TBSS. Afterwards the specimens 
were digested with 600 units/mL of collagenase type II (Worthington Biochemical Corp, 
Lakewood, NJ) in DMEM by stirring at 37°C for a maximum of 15 h. The suspension was 
then filtered, and the isolated chondrocytes were washed 3 times with DMEM containing 
10% fetal bovine serum (FBS). The viability of the isolated cells was determined using the 
trypan blue exclusion method. The cells were cultured in 175 cm2 culture flasks at 5% CO2, 
95% humidity and 37°C in DMEM containing 10% FBS. Chondrocytes were cultured in 
monolayers until confluence and then seeded onto the scaffolds. Cell-seeded scaffolds were 
cultured in 12-well tissue culture plates in DMEM supplemented with 10% FCS, 
nonessential amino acids, and 40 µg/mL of l-proline. After 2 days, 50 µg/mL of ascorbic 
acid was added. The medium was changed three times per week. Cell scaffold constructs 
were analyzed after 8 days of culture.  
In these experiments the cultured cells showed a round shaped chondrocytic phenotype as 
seen by histological examination. Regarding the distribution of cells the majority of cells was 
detectable in the upper half of the scaffold. In this area cell clusters consisting of two or more 
cells could be seen, which are typical for the middle zone of articular cartilage. With the help 
of alcian blue staining, the production of extracellular matrix components was demonstrated 
especially surrounding the cell clusters (fig 8). 
In further experiments with cultured human chondrocytes from patients who underwent 
implantation of endoprothesis due to osteoarthrosis, preliminary data revealed that in the 
presence of low dose PGE2 the seeded cells showed a chondrocytic, round shaped 
phenotype with arrangement of multiple clusters, whereas cells without PGE2 showed a 
spindle shaped fibrocytic phenotype (Brochhausen et al., 2008). 
 
 Fig. 8. Bovine chondrocytes cultivated for eight days in the combined release-scaffold 
system with round shaped chondroid phenotype (a, HE, x400), formation of chondrocyte 
clusters (b, arrow) and relevant extracellularmatrix production (b, alcian blue, x400)  
 
6. Conclusion 
In the present report we demonstrate that growth plate cartilage is a suitable model for 
strategies to target potential signalling molecules and growth factors for tissue engineering. 
Furthermore, we described the synthesis of a scaffold material with a structural design that 
gives ingrowing cells a pre-defined microenvironment similar to the cellular organization in 
native articular cartilage. Based on knowledge gained from the development of bone we 
used PGE2 as a signalling molecule for cartilage tissue engineering strategies. In this context 
we firstly immobilized this molecule in polyester-based (PLGA) microspheres and then 
incorporated these in our gelatin-based orientated scaffold. The present experiments 
confirmed the prolonged release of PGE2 from the PLGA microspheres and the beneficial 
effects of low dose PGE2 for the phenotype of bovine and human articular chondrocytes 
seeded on the three-dimensional scaffold. 
Since PLGA release systems are already used for various substances the present 
microsphere-scaffold system opens the perspective for the incorporation of further 
signalling molecules and growth factors. Furthermore, our construct facilitates the 
systematic analysis of different factors influencing the proliferation and differentiation of 
chondrocytes in an identical three-dimensional environment. For further tissue engineering 
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6. Conclusion 
In the present report we demonstrate that growth plate cartilage is a suitable model for 
strategies to target potential signalling molecules and growth factors for tissue engineering. 
Furthermore, we described the synthesis of a scaffold material with a structural design that 
gives ingrowing cells a pre-defined microenvironment similar to the cellular organization in 
native articular cartilage. Based on knowledge gained from the development of bone we 
used PGE2 as a signalling molecule for cartilage tissue engineering strategies. In this context 
we firstly immobilized this molecule in polyester-based (PLGA) microspheres and then 
incorporated these in our gelatin-based orientated scaffold. The present experiments 
confirmed the prolonged release of PGE2 from the PLGA microspheres and the beneficial 
effects of low dose PGE2 for the phenotype of bovine and human articular chondrocytes 
seeded on the three-dimensional scaffold. 
Since PLGA release systems are already used for various substances the present 
microsphere-scaffold system opens the perspective for the incorporation of further 
signalling molecules and growth factors. Furthermore, our construct facilitates the 
systematic analysis of different factors influencing the proliferation and differentiation of 
chondrocytes in an identical three-dimensional environment. For further tissue engineering 
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applications it is of interest to create gradients of signalling molecules and growth factors 
within the scaffold by establishing a graded microsphere distribution. 
In conclusion, we demonstrate in this contribution an innovative scaffold material with 
properties of a biphasic composition and the incorporation of signalling molecules with the 
perspective to improve our understanding of the triad of cells, materials and signalling 
molecules as essential elements for tissue engineering strategies.  
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applications it is of interest to create gradients of signalling molecules and growth factors 
within the scaffold by establishing a graded microsphere distribution. 
In conclusion, we demonstrate in this contribution an innovative scaffold material with 
properties of a biphasic composition and the incorporation of signalling molecules with the 
perspective to improve our understanding of the triad of cells, materials and signalling 
molecules as essential elements for tissue engineering strategies.  
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